In Brief: Ocurest Labs
This article was originally published in The Tan Sheet
Executive Summary
Ocurest Labs: Ocurest medicated eye drops holds a 3.2% share of the category unit sales in March, up from 2.1% in February and 1.7% in January, based on data from Information Resources, Inc., the firm says. The product, in redness relief and lubricating formulas, had first quarter sales of $448,000. The Palm Beach, Fla.-based company attributes its share gain to national advertising that began in late 1996 following a launch earlier last year. The product is manufactured by Bausch & Lomb. Ocurest plans to introduce an allergy relief formula early next year under a licensing agreement with Ciba/Novartis ("The Tan Sheet" March 24, In Brief). The medicated eye drops market is led by Pfizer's Visine with a 45% share, followed by Ross Labs' Clear Eyes and Murine, with a 19% share and Bausch & Lomb (Sensitive Eyes, Moisture Drops and Opcon), with 11%..